Niox Group PLC
LSE:NIOX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Atakey Patates Gida Sanayi ve Ticaret AS
IST:ATAKP.E
|
TR |
|
A
|
AnGes Inc
OTC:AMGXF
|
JP |
|
S
|
Square Enix Holdings Co Ltd
OTC:SQNXF
|
JP |
|
Husqvarna AB
STO:HUSQ B
|
SE |
|
STO Express Co Ltd
SZSE:002468
|
CN |
|
D
|
Dingzing Advanced Materials Inc
TWSE:6585
|
TW |
|
Petpal Pet Nutrition Technology Co Ltd
SZSE:300673
|
CN |
|
H
|
Hardwyn India Ltd
NSE:HARDWYN
|
IN |
|
L
|
Lens Technology Co Ltd
SZSE:300433
|
CN |
Niox Group PLC
Total Liabilities
Niox Group PLC
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Niox Group PLC
LSE:NIOX
|
Total Liabilities
£2.5m
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-29%
|
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Total Liabilities
$107.6m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Total Liabilities
£686.2m
|
CAGR 3-Years
64%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
|
Compass Pathways PLC
NASDAQ:CMPS
|
Total Liabilities
$263.2m
|
CAGR 3-Years
154%
|
CAGR 5-Years
107%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Total Liabilities
£417.3m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
2%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Total Liabilities
£234.4m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
27%
|
CAGR 10-Years
19%
|
|
Niox Group PLC
Glance View
Circassia Group Plc is a holding company, which engages in the development and commercialization of respiratory products. The company is headquartered in Oxford, Oxfordshire and currently employs 128 full-time employees. The company went IPO on 2014-03-13. The Company’s product NIOX uses patented technology to measure fractional exhaled nitric oxide (FeNO). Its NIOX FeNO measurement and monitoring products are used by physicians around the globe to help improve asthma diagnosis and management. The firm offers NIOX VERO, a point of care device for the accurate measurement of nitric oxide (NO) as a biomarker of airway inflammation to help diagnose and manage asthma. The device is used by healthcare professionals to improve asthma care, which assists diagnosis, determining responsiveness to inhaled corticosteroids, tailoring inhaled steroid use, monitoring treatment compliance, and reducing the likelihood of exacerbations in at-risk patients compared to traditional monitoring. The firm provides products and services in around 50 countries.
See Also
What is Niox Group PLC's Total Liabilities?
Total Liabilities
2.5m
GBP
Based on the financial report for Dec 31, 2025, Niox Group PLC's Total Liabilities amounts to 2.5m GBP.
What is Niox Group PLC's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
-29%
Over the last year, the Total Liabilities growth was -11%. The average annual Total Liabilities growth rates for Niox Group PLC have been -47% over the past three years , -40% over the past five years , and -29% over the past ten years .
